AI-powered contentSome parts of this article are powered by AI.
Share this article
Gotrade News - AN2 Therapeutics (ANTX) reported a net loss of $8.0 million for the third quarter ended September 30, 2026, compared to $9.4 million a year earlier, according to the company's official release on Monday, November 9, 2026. Cash, cash equivalents and investments were $80.2 million at quarter end.
Regular-session close on November 9, 2026, New York time. Prices and changes: Yahoo Finance, cross-checked against the closing price on Nasdaq.com. Market cap: that close times the shares outstanding on the latest 10-Q or 10-K cover (SEC EDGAR).
AN2 Therapeutics Earnings Details
Research and development expenses for the third quarter of 2026 were $5.7 million, compared to $7.0 million for the same period in 2025. The company attributed the decrease to lower preclinical and research studies expenses, other miscellaneous expenses and clinical trial expenses, partially offset by higher personnel-related expenses and chemistry manufacturing and controls (CMC) expenses.
General and administrative expenses were $2.9 million, compared to $3.0 million for the same period in 2025, which the company said reflected decreased personnel-related expenses, partially offset by increased professional and outside services expenses and other miscellaneous expenses. Interest income was $0.7 million, consistent with $0.7 million a year earlier. The company projects that its existing cash, cash equivalents and investments will sustain operations into 2029 under its current operating plan.
Why It Matters for ANTX
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics from its boron chemistry platform, and the release pairs the quarterly results with pipeline updates. “The third quarter was marked by continued execution across our clinical pipeline and meaningful progress in expanding the opportunities enabled by our boron chemistry platform,” said Eric Easom, Co-Founder, Chairman, President and CEO. According to the company, its global Phase 2 study of oral epetraborole in polycythemia vera (PV) is cleared to proceed in all planned jurisdictions, including U.S. FDA clearance of its IND, and the company anticipates commencing enrollment by the end of 2026 and releasing Part 1 data periodically throughout 2027.
The company also said enrollment is ongoing in an 84-patient Phase 2 investigator-initiated trial of epetraborole in M. abscessus lung disease, with topline results anticipated in late 2027, subject to enrollment progress. It is advancing startup activities for a Phase 2 study of AN2-502998 in chronic Chagas disease, and it selected AN2-504661 as an oral development candidate for hypophosphatasia (HPP), with a Phase 1 clinical study planned for the second half of 2027.
Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA). This content is for educational purposes only and does not constitute financial advice. Always do your own research (DYOR) before investing.
M. Alfathan Rahman is a content writer with over 3 years of experience developing digital content strategies across various industries, including fintech. He has experience producing content for tax-related websites and financial education platforms. His focus areas include data research, and crafting financial articles that are informative, accurate, and accessible to investors of all experience levels.
